Patients with late-onset rheumatoid arthritis experienced greater functional impairment over 5 years, compared against those with younger-onset disease.

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Medically reviewed by Stella Bard, MD Osteoarthritis (OA) and rheumatoid arthritis (RA) are two of the most common types of ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.